Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs.

Abstract

Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs

Keywords

• Targeted inhibition
• IL-6 signaling
• tocilizumab
• rheumatoid arthritis
• DMARDs